Rchr
J-GLOBAL ID：201801012163116681   Update date: Oct. 08, 2024

Hosen Naoki

ホセン ナオキ | Hosen Naoki
Affiliation and department：
Osaka University

About Osaka University


Research field  (1)： Hematology and oncology
Research keywords  (5)： 血液内科学 ,  Cancer Stem Cell ,  Multiple myeloma ,  antibody therapy ,  CAR T cell therapy
Research theme for competitive and other funds  (25)：
  • 2023 - 2026 Unraveling the mechanism of poor response to anti-comlement drug in cold agglutinin disease treatment
  • 2023 - 2026 胸腺上皮性腫瘍の腫瘍間質をターゲットとした治療戦略の探索
  • 2023 - 2025 免疫監視能強化CAR-NK細胞を用いた がんの再発予防法の開発
  • 2023 - 2025 自己糖鎖認識機構の制御によりがん認識能を増強したCAR-NK細胞の開発
  • 2022 - 2025 Identification of glioblastoma-specific antigens for chimeric antigen receptor T cell therapy
Show all
Papers (151)：
  • Tetsuro Tachi, Noriyuki Kijima, Hideki Kuroda, Syunya Ikeda, Koki Murakami, Tomoyoshi Nakagawa, Moto Yaga, Kanji Nakagawa, Reina Utsugi, Ryuichi Hirayama, et al. Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model. Cancer immunology, immunotherapy : CII. 2024. 73. 12. 256-256
  • Yutaka Shimazu, Junya Kanda, Teruhito Takakuwa, Yoshiyuki Onda, Kentaro Fukushima, Masaaki Hotta, Shin-Ichi Fuchida, Nobuhiko Uoshima, Yuji Shimura, Hirokazu Tanaka, et al. The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients. Annals of hematology. 2024
  • Moto Yaga, Kana Hasegawa, Shunya Ikeda, Miwa Matsubara, Takashi Hiroshima, Toru Kimura, Yuya Shirai, Wibowo Tansri, Hirofumi Uehara, Mana Tachikawa, et al. CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapy. Scientific reports. 2024. 14. 1. 17917-17917
  • Ritsuko Nakai, Takafumi Yokota, Masahiro Tokunaga, Mikiro Takaishi, Tomomasa Yokomizo, Takao Sudo, Henyun Shi, Yoshiaki Yasumizu, Daisuke Okuzaki, Chikara Kokubu, et al. A newly identified gene Ahed plays essential roles in murine haematopoiesis. Nature communications. 2024. 15. 1. 5090-5090
  • Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, et al. The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer immunology, immunotherapy : CII. 2024. 73. 7. 135-135
ｍore...
MISC (41)：
  • 水田惠美子, 福島健太郎, 濱田雅隆, 水谷陽, 長谷川千紘, 山口優太, 中井りつ子, 倉重隆明, 日野彬央, 草壁信輔, et al. Analysis of HSCT for myelofibrosis treated with pre-and post-transplant ruxolitinib. 日本造血・免疫細胞療法学会総会プログラム・抄録集. 2024. 46th
  • 水田惠美子, 福島健太郎, 濱田雅隆, 水谷陽, 長谷川千紘, 山口優太, 倉重隆明, 日野彬央, 草壁信輔, 上田智明, et al. Experience of ide-cel use in relapsed/refractory multiple myeloma at our institution. International Journal of Myeloma (Web). 2024. 14. 3
  • 遠藤誉也, 日野彬央, 草壁信輔, 上田智朗, 数藤孝雄, 藤田二郎, 福島健太郎, 保仙直毅. 血液透析中の患者に対し移植後シクロホスファミド併用末梢血幹細胞移植を施行した1例. 臨床血液. 2023. 64. 8
  • 黒田秀樹, 木嶋教行, 館哲郎, 村上皓紀, 中河寛治, 川本有輝, 宇津木玲奈, 平山龍一, 沖田典子, 香川尚己, et al. Identification of Therapeutic Target Antigens using patient derived glioblastoma and Their Application to CAR-T Therapy. 日本脳腫瘍学会学術集会プログラム・抄録集. 2023. 41st
  • 村上皓紀, 木嶋教行, 黒田秀樹, 館哲郎, 中河寛治, 宇津木玲奈, 川本有輝, 平山龍一, 沖田典子, 香川尚己, et al. Modification of RNA sequencing strategy to identify glioblastoma specific molecules. 日本脳腫瘍学会学術集会プログラム・抄録集. 2023. 41st
ｍore...
Patents (3)：
  • 抗体
  • 抗体
  • 形質細胞の腫瘍性増殖をきたす疾患の治療薬
Education (2)：
  • 1998 - 2002 大阪大学大学院 医学系研究科
  • 1988 - 1994 Osaka University Faculty of Medicine
Professional career (1)：
  • 医学博士 (大阪大学)
Work history (12)：
  • 2021/11 - 現在 Osaka University Immunolgy Frontier Research Center Cellular Immunotherapy Professor
  • 2020/01 - 現在 Osaka University Graduate School of Medicine Department of Hematology and Oncology Professor
  • 2014/04 - 2019/12 Osaka University Graduate School of Medicine
  • 2009/04 - 2014/03 Osaka University Graduate School of Medicine
  • 2007/05 - 2009/03 Osaka University Graduate School of Medicine
Show all
Awards (1)：
  • 2007 - 日本白血病研究基金 若手研究奨励賞
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM